INTRODUCTION {#S1}
============

The skin and mucosal surfaces of humans are colonized by a wide variety of commensal microorganisms that outnumber human somatic cells^[@R1]^. The GI tract harbors the greatest quantity and diversity of microorganisms. Traditionally appreciated for its function to facilitate metabolism and nutrient intake, intestinal microbiome has now been intensively studied for its role in maintaining host immune homeostasis^[@R2]--[@R5]^. The composition of intestine microbiota, or enterotype, influences host predisposition to autoimmune disorders affecting tissue sites proximal and distal to the intestine^[@R6]--[@R11]^. EAE is an animal model of human multiple sclerosis where self-reactive immune-pathology targets the central nervous system (CNS). While colonization of germ-free mice with *segmented filamentous bacteria* (SFB) increases susceptibility to EAE, oral administration with *Bacteroides fragilis*, *Bifidobacterium animalis* and other probiotic mixtures have been shown to prevent EAE development^[@R12]--[@R16]^. These studies associated different commensal strains with opposite outcomes of CNS autoimmunity.

Commensal bacteria can be characterized as symbionts or pathobionts, depending on the survival strategies employed. Symbionts live in a lifelong mutualistic pattern with the host whereas pathobionts are often opportunistic pathogens^[@R5]^. To facilitate co-existence, symbionts must limit aggressive immune attacks or induce immune tolerance by utilizing some microbial products as symbiosis factors. In this context, polysaccharide A (PSA) produced by the human intestinal symbiont *Bacteroides fragilis* has been identified as a model molecule that elicits beneficial immune responses for both commensals and host. *B. fragilis* lacking PSA have defective mucosal colonization due to inability to restrain Th17 responses^[@R17]^. Initially found to direct host adaptive immunity maturation, PSA then reveals its capability of resolving autoimmunity^[@R18],[@R19]^. Oral treatment with PSA prevents murine experimental colitis by inducing IL-10^+^Foxp3^+^ Tregs^[@R20]^. Notably, PSA also suppresses CNS inflammation during murine EAE, operational through IL-10 and CD103^+^ DCs^[@R21]^. The precise signal by which PSA imparts on the adaptive immune cells, particularly the CD4^+^ T cells, to prevent disease progression remains uncertain.

Microbial ligands are detected by host innate immunity as microbe-associated molecular patterns (MAMPs). Sensing of microbial ligands by toll-like receptors (TLRs) can mobilize innate immunity and subsequently activate adaptive immunity, leading to the host exclusion of microbes^[@R22]^. PSA, however, represents a reverse example where TLR detection of microbial ligand promotes the co-existence of symbionts with the host. TLR2 signals on CD4^+^ T cells are crucial for PSA elicitation of immunologic tolerance toward *B. fragilis* intestinal colonization^[@R17]^. Further, while many other microbial ligands sensed by TLRs act as adjuvants to exacerbate autoimmunity, detection of PSA by TLR2 resolves intestinal inflammation^[@R20],[@R23],[@R24]^. Our previous study has shown that oral treatment with *B. fragilis* PSA prevents murine EAE both prophylactically and therapeutically^[@R21]^. In this study, we demonstrate thatTLR2 signaling is essential for PSA-mediated modulation of CNS immune-pathology. The expansion of CD39^+^CD4^+^ T cells downstream TLR2 is responsible for PSA-mediated immune-regulation. CD39 defines regulatory phenotypes in CD4 T cells irrespective of Foxp3 co-expression and is essential for the protective function of PSA during CD4^+^ T cell-driven neuroinflammation.

RESULTS {#S2}
=======

*Bacteroides fragilis* PSA controls CNS inflammation via TLR2 {#S3}
-------------------------------------------------------------

To evaluate whether TLR2 is required for PSA regulation of CNS inflammatory disease, WT or TLR2^KO^ mice were given oral prophylactic treatment with PSA or PBS during EAE. Consistent with previous results, treatment with PSA in WT mice delayed the clinical onset and progression of EAE, as reflected by the clinic curve and cumulative score. The protective effects were abrogated in TLR2^KO^ mice. At basal level, PBS-treated WT and TLR2^KO^ mice developed comparable severity of EAE ([Fig. 1A, B](#F1){ref-type="fig"}). Histological assays confirmed the clinical results. H&E staining ([Fig. 1C](#F1){ref-type="fig"} first and third columns) revealed that PSA inhibited the robust lymphocyte infiltration into the CNS (spinal cord and brain) in WT mice. This inhibitory function of PSA was abrogated in TLR2^KO^ mice. Lymphocytic influx leads to demyelination in EAE. As LFB staining ([Fig. 1C](#F1){ref-type="fig"} second column) showed, whilst PSA reduced demyelination lesions of the spinal cord in WT mice, this effect was not observed in TLR2^KO^ mice. Oral therapeutic treatment with PSA also protects against EAE via TLR2 ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

CNS inflammation is the hallmark of both human multiple sclerosis and murine EAE^[@R25],[@R26]^. To investigate whether PSA restricts CNS inflammation via TLR2, transcriptional levels of genes in the brain were compared for PSA versus PBS-treated WT mice and PSA-treated WT versus TLR2^KO^ mice ([Fig. 1D](#F1){ref-type="fig"}). PSA down-regulated multiple genes through TLR2 that encode for (1) transcription factors *Tbx21* (*T-bet*) and *Stat4*, that govern Th1 cell development; (2) pro-inflammatory cytokines IL-17, IL-6 and IL-12p40, that mediate Th1/Th17 as well as TNFα; (3) chemokines IP-10 (CXCL10), MCP-1 (CCL2), Rantes (CCL5), MIP-1α (CCL3) and MIP-1β (CCL4), which are attractants for T cell, macrophages and monocytes. In TLR2^KO^ mice, PSA failed to restrict or might exacerbate the expression of inflammation-related genes. The expression trend of chemokines in the CNS corroborated the histological visualization by H&E staining. Taken together, these results demonstrated that TLR2 is required for *B. fragilis* PSA control of CNS inflammation during EAE.

PSA triggers specific signal on CD4 T cells via TLR2 {#S4}
----------------------------------------------------

CD4^+^ T cells are the primary immune population that drives EAE pathogenesis^[@R25]^. Cervical lymph nodes (CLNs) are important anatomical sites for immune cells draining to the CNS during autoimmunity^[@R27]^. Flow cytometric profiles of CLN CD4^+^ T cells were compared for PSA-or PBS-treated WT or TLR2^KO^ mice by mean fluorescence intensity (MFI)([Fig. 2](#F2){ref-type="fig"}). A pool of CD4^+^ T cell lineage and functional markers was included. CD39 was identified as a significant PSA- and TLR2-specific signal, which is correlated by comparing positive subset frequencies in [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}. Both CD39 and CD73 are classified as ectonucleotidase, whose main function is to coordinate the conversion of extracellular ATP/ADP into adenosine^[@R28],[@R29]^. CD73 signal on CLN CD4^+^ T cells, however, did not appear to be regulated through PSA/TLR2 axis ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).

PSA expands CD39^+^ CD4 T cells via TLR2 at specific tissues {#S5}
------------------------------------------------------------

To further characterize *in vivo* regulation of CD39 signal on CD4 T cells, we examined the frequencies of CD39^+^ subset within CD4 T cells in EAE-induced WT or TLR2^KO^ mice orally treated with PBS or PSA. Consistent with MFI trends in [Fig. 2](#F2){ref-type="fig"}, representative histograms showed that PSA stimulated CD39 signal on CD4 T cells via TLR2 at both CLNs ([Fig. 3A](#F3){ref-type="fig"}) and mesenteric lymph nodes (MLNs) ([Fig. 3B](#F3){ref-type="fig"}). To determine whether the TLR2-dependent PSA expansion of CD39^+^ CD4 T cell subsets is local or systemic, frequencies of CD39^+^ subsets among CD4 T cells were quantified for CLNs, MLNs, spleen, whole blood ([Fig. 3C](#F3){ref-type="fig"}) and immunization DLNs ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Of these tissue sites, only CLNs and MLNs displayed TLR2-dependent PSA up-regulation of CD39^+^ CD4 T cells. CD39^+^ frequencies within splenic CD4 T cells were not affected. CD39^+^ frequencies within blood and DLN CD4 T cells were down-regulated with PSA treatment. PSA does not significantly alter CD4 T cell-derived CD39 signals via TLR2 in naïve mice ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Thus, the TLR2-dependent PSA expansion of CD39^+^ CD4 T cells during EAE is localized. Amongst lymphocytes, CD39 is expressed on both CD4^+^ T cells and B cells^[@R29]^. To investigate whether B cell-derived CD39 signal is concomitantly regulated by PSA/TLR2 axis at the affected sites, CD39^+^ frequencies within CD19^+^ B cells were quantified for CLNs and MLNs ([Fig. 3D](#F3){ref-type="fig"}). Though CD19^+^ B cells showed higher basal level CD39^+^ frequencies compared to CD4^+^ T cells, PSA treatment did not significantly alter CD39^+^ frequencies within B cells. *In vitro*, PSA stimulated CD39 signals on CD4 T cells through DCs ([Supplementary Fig. 6A--C](#SD1){ref-type="supplementary-material"}). In summary, these results show that TLR2-dependent PSA-mediated enhancement of CD39 signal is both CD4 T cell-specific and tissue site-specific.

Phenotyping CLN-sourced CD39^+^ versus CD39^−^ CD4 T cells {#S6}
----------------------------------------------------------

The phenotype of CD39^+^ CD4 T cells at inflammatory sites is not well understood. As PSA robustly stimulates CD39^+^CD4 T cells at specific tissue sites during EAE, our study offers the opportunity to examine differences between inflammatory-state CD39^+^ andCD39^−^ CD4 T cells. CLNs were harvested from PSA-treated EAE-affected mice. Total CD4^+^ T cells were gated into CD39^+^ and CD39^−^ subsets and phenotyped by flow cytometry. The expression level of each individual marker was described by both histograms ([Fig. 4A](#F4){ref-type="fig"}) and MFI ([Fig. 4B](#F4){ref-type="fig"}). We found that the CD39^+^ CD4 T cell subset, as compared to the CD39^−^ CD4 T cell subset, expressed remarkably higher levels of IL-10 and significantly higher levels of latency-associate peptide (LAP), denoting TGF-β production. As for surface immune-regulatory markers, the CD39^+^ CD4 T cell subset exhibited significantly higher levels of programmed death-1 (PD-1), glucocorticoid-induced TNFR-related gene (GITR), cytotoxic T-lymphocyte antigen 4(CTLA-4), inducible T-cell costimulator (ICOS) and relatively higher expression of lymphocyte activation gene-3 (LAG-3) and V-domain Ig suppressor of T cell activation (VISTA). PD-1, GITR, CTLA-4, ICOS and LAG-3 are all co-inhibitory molecules with known ligands^[@R30]--[@R32]^; VISTA, is a co-inhibitory molecule with as yet no recognized ligand(s)^[@R33]^. Conversely, 4-1BB (CDw137), a co-stimulatory molecule, was noted at lower levels on the CD39^+^ CD4 T cell subset^[@R34]^.

The expression of CD25 and CD44 positively correlated with CD39 in CD4 T cells, whereas CD62L and CD69 did not. Moreover, CD40L (CD154) expression was enriched within CD39^+^ CD4 T cells. These in general indicate that CD39^+^ CD4 T cell is an activated subset responsive to PSA exposure. CD39^+^ CD4 T cell subset expressed remarkably higher CD49d and CD29 compared to CD39^−^ CD4 T cell subset. CD49d (α4 integrin) and CD29 (β1 integrin) form very late antigen-4 (VLA-4), a vital CNS-homing marker^[@R35]^. Increased level of CD73 was seen in CD39^+^ as opposed to CD39^−^ CD4 T cell subset. CD39^+^ CD4 T cell subset expressed relatively lower CD127 but remarkably higher CD103. CD127 (IL-7Rα) is down-regulated on Treg cells^[@R36]^. CD103 (αE integrin) is mostly expressed by IELs but also by a subset of Tregs^[@R37]^. Collectively, CD39^+^ CD4 T cell is phenotyped as a regulatory subset with abundant expression of multiple immune-suppressive molecules. The regulatory phenotype of CD39^+^ CD4 T cell subset was not confined to either tissue sites or treatment, as CD39^+^ CD4 T cell derived from other tissues or treatment groups displayed similar phenotypic pattern ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}).

CD39 defines regulatory phenotypes regardless of Foxp3 {#S7}
------------------------------------------------------

Delineation of murine CD4 T cells by CD39 and Foxp3 revealed four populations: CD39^+^Foxp3^+^, CD39^−^Foxp3^+^, CD39^+^Foxp3^−^, and CD39^−^Foxp3^−^ ([Supplementary Fig. 8A](#SD1){ref-type="supplementary-material"}). To determine whether CD39 could confer regulatory phenotypes on its own, we further profiled CD39^+^ versus CD39^−^ Foxp3^+^ CD4 Treg ([Supplementary Fig. 8B](#SD1){ref-type="supplementary-material"}) and Foxp3^−^ CD4 Teff ([Supplementary Fig. 8C](#SD1){ref-type="supplementary-material"}) subsets sourced from CLNs of PSA-treated EAE-affected mice. The same markers as in [Fig. 4](#F4){ref-type="fig"} were used and quantified by MFI values. CD39 defined a similar expression profile of markers in Foxp3^+^ CD4 Tregs as in total CD4 T cells with exception to VISTA, CD40L and CD127 ([Supplementary Fig. 8B](#SD1){ref-type="supplementary-material"}). Further, CD39 defined a similar expression profile in Foxp3^−^ CD4 Teffs excluding VISTA, CD73, CD127 and CD40L ([Supplementary Fig. 8C](#SD1){ref-type="supplementary-material"}). Collectively these data demonstrate that CD39 expression in response to PSA treatment is associated with multiple immune-suppressive features independent of Foxp3 co-expression.

CD39 is essential for PSA-mediated immuno-regulation in EAE {#S8}
-----------------------------------------------------------

To investigate the requirement for CD39 signaling in PSA-mediated suppression of CNS inflammation, WT or CD39^KO^ mice were orally gavaged with PSA before and after the induction of sub-optimal active EAE. CD39 deficiency abrogated the immune-regulatory function of PSA ([Fig. 5A--B](#F5){ref-type="fig"}). WT and CD39^KO^ mice developed similar basal levels of EAE ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). The similar clinic trend was observed in optimal EAE ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). The clinic results in [Fig. 5A--B](#F5){ref-type="fig"} were confirmed by histological assays. PSA-mediated suppression of lymphocyte influx and demyelinating lesions in the CNS was prominent in WT mice but diminished in CD39^KO^ mice ([Fig. 5C](#F5){ref-type="fig"}). CD39 is required for PSA control of both neural and systemic inflammation during EAE ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). PSA-treated WT mice exhibited lower T cell activation levels than did PSA-treated CD39^KO^ mice. The trend was evident at CLN and also seen at MLN, but not at spleen or whole blood ([Fig. 5D](#F5){ref-type="fig"}), correlating with the PSA-mediated site-specific expansion of CD39^+^ CD4 T cells.

To test whether CD39 differentially regulates pro- versus anti-inflammation cytokine responses to PSA or neural auto-antigen MOG~35--55~, splenocytes were isolated from PSA-treated, EAE-affected WT and CD39^KO^ mice and recalled with dose-escalating PSA, MOG~35--55~ peptide or combined *in vitro* for 48 hrs. IL-10 and IL-17A production was measured by ELISA. Although basal IL-10 release was comparable between WT and CD39^KO^ splenocytes, PSA dosage-dependently increased IL-10 release from WT but not CD39^KO^ splenocytes. MOG~35--55~ peptide suppressed IL-10 release from WT and CD39^KO^ splenocytes. Adding PSA to MOG~35--55~ peptide restored dosage-dependent IL-10 release from WT splenocytes; IL-10 response of CD39^KO^ splenocytes remained compromised ([Fig. 5E](#F5){ref-type="fig"}). In contrast, PSA decreased IL-17A release from WT splenocytes, whereas CD39^KO^ splenocytes displayed elevated IL-17A response when contrasted to WT splenocytes re-stimulated with dose-escalating PSA, MOG~35--55~ peptide or combined *in vitro* ([Fig. 5F](#F5){ref-type="fig"}). The requirement of CD39 in IL-10 responsiveness is antigen (PSA)-specific, as splenocytes from the same mice groups showed comparable *in vitro* IL-10 response to anti-CD3/CD28 beads ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}). IFNγ release, however, was only slightly enhanced in CD39^KO^as opposed to WT splenocytes ([Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). CD39 is also crucial for PSA-induced IL-10 release from CD4 T cells *in vitro* ([Supplementary Fig. 6D](#SD1){ref-type="supplementary-material"}). Thus, PSA-mediated reciprocal regulation of anti- versus pro-inflammatory cytokines is CD39-dependent.

To determine whether CD4 T cell-restricted CD39 signaling is required for PSA's regulatory function during EAE, splenic CD4 T cells isolated from EAE-induced PSA- or PBS-treated WT or CD39^KO^ donor mice were introduced into Rag^KO^ recipients, which lack mature B and T cells. Optimal active EAE was induced following reconstitution. As clinic curve revealed ([Fig. 5G](#F5){ref-type="fig"}), the recipient group given PSA-modified WT CD4 T cells showed slower EAE progression. All groups culminated in comparable severity of EAE by day 21. Cumulative score quantified clinical differences ([Fig. 5H](#F5){ref-type="fig"}). Rag^KO^ recipients receiving naïve WT or CD39^KO^ CD4 T cells were given the same regimen ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). In both settings, CD4 T cell-specific CD39 signaling is required for PSA-mediated control of EAE. In conclusion, TLR2 signaling is essential for PSA-mediated protection against CNS autoimmunity and localized expansion of CD39^+^ CD4 T cells defined as an indispensable regulatory subset both phenotypically and functionally.

DISCUSSION {#S9}
==========

There exists a dynamic equilibrium in host-microbial mutualism. From the co-evolutionary perspective, both hosts and commensals must evolve regulatory mechanisms to quench deleterious mucosal and subsequent systemic inflammation. On the host side, several molecules have been discovered as the negative regulators of TLR-mediated inflammation such as the single immunoglobulin IL-1 receptor related molecule (SIGIRR), peroxisome proliferators-activated receptor-γ (PPARγ), non-specific IgAs and inhibitory cytokines, for instance IL-10^[@R38],[@R39]^. On the commensal side, *B. fragilis* capsular polysaccharide PSA typifies a molecular pattern that exploits TLR2 to deliver negative immune signals. The regulatory capacity of PSA could be due to its zwitterionic structure, as previous studies indicated that disruption of this structure inhibited PSA functions *in vitro*^[@R40]^.

MS is a CNS-targeting immune-mediated disease affected by both genetic and environmental factors. Murine EAE studies suggest that modification of intestinal commensals can alter disease outcomes^[@R41],[@R42]^. The intestine is an important site for peripheral education of immune cells. Exposure to different commensal products may differentiate the CNS-antigen-reactive lymphocytes into an auto-aggressive or self-restrictive phenotype. Our previous studies identified that *B. fragilis* PSA could alleviate CNS inflammation^[@R21]^. We herein report that TLR2 is critical for PSA-mediated prevention of clinic progression, CNS demyelination and inflammation during EAE. TLR2 induced the tissue-specific expansion of a key regulatory CD39^+^ CD4 T cell subset.

Whether detection of PSA via APC-restricted TLR2 is critical for CD4^+^ T cell acquisition of CD39 signal remains uncertain. It has been found that vesicle-associated PSA imposes specific genetic changes on DCs through TLR2^[@R24]^. Importantly, our previous studies indicated that CD103^+^ DCs accumulated at CLNs during PSA treatment of EAE and displayed elevated expression of TLR2 and MHC II^[@R21]^. Concomitant local expansion of both DC subsets and CD39^+^ CD4 T cells suggests that more than one pathway besides TLR2 may be involved in the process, which is currently under investigation.

In this study, TLR2 liaised the connection between the commensal symbiosis factor PSA and CD39, a cell surface ectonucleotidase member of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family. Extracellular ATP activates multiple immune functions that lead to inflammation^[@R43]^. Intestinal luminal contents comprise high concentrations of ATP produced by commensal bacteria. It has been reported that commensal-derived ATP is capable of inducing IL-6 and IL-23 production by lamina propria APCs and expands intestinal Th17 cells^[@R44]^. In this sense, *B. fragilis* PSA stimulation of CD39 signaling may represent a symbiont-evolved strategy to limit the excessive inflammatory response to commensal release of ATP. Indeed, we found that the selective induction of CD39 signaling on CD4^+^ T cell is required for PSA immune-regulation at the systemic level. PSA seems more optimal in controlling Th17 than Th1 response, which is dependent on CD39 signaling. CD39 and CD73 coordinate hydrolysis of extracellular ATP to adenosine. The generated extracellular adenosine further inhibits TCR-activated effector T cells via cognate A2a receptors^[@R28]^. Consistently, a reciprocal decrease of activated CD4^+^ T cells seems to accompany the increase of CD39^+^ CD4 T cells at CLNs during PSA treatment of EAE.

CD39 is essential for the regulatory function of Foxp3^+^ CD4 Tregs^[@R29]^. It has been reported that CD39^+^Foxp3^+^ CD4 Tregs but not CD39^−^Foxp3^+^ CD4 Tregs can effectively suppress Th17^[@R45]^. However, several studies indicate that CD39^+^ CD4 T cell is in itself a regulatory subset regardless of Foxp3^[@R46],[@R47]^. It is speculated that CD39^+^ CD4 T cell consists of both Foxp3^+^ Tregs and Tr1 cells. Here we show that CD39^+^ CD4 T cell expressed remarkably higher IL-10 than CD39^−^ CD4 T cell. Moreover, CD39 is required for PSA-triggered IL-10 response. It is feasible that CD39 defines immuno-regulatory phenotype in both CD4 T cells and Foxp3^+^ CD4 Tregs. Previous studies showed that whilst PSA induced a limited quantitative increase of Foxp3^+^ CD4 Tregs, it robustly imprinted a functional suppressive genetic profile on Foxp3^+^ CD4 Tregs^[@R20]^. Therefore, CD39 is possibly the key signal that directs CD4 Tregs functional maturation in response to commensal antigen exposure. Collectively, this study on *B. fragilis* PSA deepens our understanding of the therapeutic potential and mechanism of commensal products in modulating CNS autoimmunity.

METHODS {#S10}
=======

Mice and treatment {#S11}
------------------

Eight-week old femaleC57BL/6 mice were obtained from the Jackson Laboratories (Bar Harbor, ME). TLR2^KO^ mice were obtained from Dr. Brent L. Berwin (Dartmouth College). IL-10 Thy1.1 reporter mice (10BiT) were obtained from Dr. Casey T. Weaver (University of Alabama at Birmingham) and crossed with TLR2^KO^ strain by Yan Wang. CD39^KO^ mice were obtained from Dr. Simon C. Robson (Harvard University). Rag-1, 2 DKO mice (Rag^KO^) were obtained from Dr. Mary Jo Turk (Dartmouth College). Mice were treated with 100 μg of purified *B. fragilis* PSA or PBS control by oral gavage every 3 days. Treatment begins 6 days before EAE induction and terminates 9 days after disease induction. All animal care and procedures were in accordance with protocols approved by the Institutional Animal Care and Use Committee of Dartmouth College.

EAE induction {#S12}
-------------

Active optimal or sub-optimal EAE was induced with s.c. injection of 200 or 160 μg MOG~35--55~ peptide (Peptides International; Louisville, KY) respectively in 150 μl of Complete Freund's Adjuvant (Sigma-Aldrich, St. Louis, MO). On day 0 and 2 post-immunization, i.p. injection of 400 or 300 ng of *Bordetella pertussis* toxin (PT; List Biological Laboratories, Campbell, CA) was respectively performed for optimal or suboptimal EAE induction. For passive EAE in this study, Rag^KO^ mice received i.v. injection of 3 × 10^6^ purified splenic CD4^+^ T cells from indicated donors 2 weeks before active optimal EAE induction. EAE severity was scored daily using the standard scale.

Histological analysis {#S13}
---------------------

Transversal sections of spinal cords or brain stems were dissected from diseased animals and fixated with 10% formalin overnight. Paraffin-embedded samples were stained with hematoxylin and eosin (H&E) method for visualizing leukocyte infiltration or with luxol fast blue (LFB) method for assessing demyelination. Pathology Translational Research Division of Dartmouth-Hitchcock Medical Center (DHMC) performed all histology staining.

Quantitative real-time PCR {#S14}
--------------------------

1 μg of mRNA was purified by QIAgen RNeasy kit (Qiagen, Germantown, MD) and reverse transcribed by MultiScribe Reverse Transcriptase (Invitrogen, Carlsbad, CA). cDNA(200 ng) was amplified using SYBR Green PCR Master Mix (Applied Biosystems, Fostor City, CA) on Bio-Rad CFX96 touch systems. Relative gene expression (duplicates) were normalized to β-actin and calculated using the CT method, where relative expression = 2\^(exp --actin) \*1000.

Enzyme-linked immunosorbent assay {#S15}
---------------------------------

Specific ELISA kits (Biolegend, San Diego, CA) were used to quantify cytokine levels in supernatants. Cells were cultured in 96-well or 48-well tissue plates at 2 × 10^6^ cells/ml concentration in the presence of indicated soluble reagents or anti-CD3/CD28 Dynabeads (Invitrogen, Carlsbad, CA) for 48 hrs and supernatants were collected.

Flow cytometric analysis {#S16}
------------------------

Singe cell preparations were isolated from indicated tissue sites and flow stained. Fluorochrome-conjugated mAbs specific to mouse CD4 (clone GK1.5), CD19 (clone 6D5), CD25 (clone PC61.5), CD29 (clone HMβ1-1), CD39 (clone 24DMS1), CD40L (clone MR1), CD44 (clone IM7), CD49d (clone R1-2), CD62L (clone MEL-14), CD69 (clone H1.2F3), CD73 (Clone eBioTY/11.8), CD103 (clone 2E7), CD127 (clone A7R34), 4-1BB (clone 17B5), GITR (clone DTA-1), ICOS (clone 7E.17G9), LAG-3 (clone eBioC9B7W), LAP (clone TW7-16B4), PD-1 (clone 29F.1A12) and Thy1.1 (clone OX-7) (1:400 dilution, Biolegend or eBioscience) were used in various combinations for cell surface staining. Biotin-labeled anti-VISTA mAb was provided by Dr. Li Wang (Medical College of Wisconsin). The Fc receptor was blocked by CD16/32 antibody (Biolegend). For Foxp3 (1:400 dilution; clone FJK-16s, eBioscience) and CTLA-4 (1:400 dilution; clone UC10-4B9, Biolegend), cells were treated by eBioscience intracellular fixation/permeabilization buffer set and intracellular staining was performed. Stained cells were assayed by MACSQuant Analyzers (Miltenyi, Bergisch Gladbach, Germany).

Cell purifications {#S17}
------------------

Splenic CD4^+^ T cells were enriched from with mouse CD4^+^ T cell isolation kit (StemCell Technologies, Vancouver, Canada) according to provided protocols.

Statistical analysis {#S18}
--------------------

Two-tailed Student's *t* test was used to show statistical differences of mRNA relative expression in qRT-PCR, fluorescence intensity or cell frequencies in FACS and cytokine levels in ELISA. ANOVA followed by post-hoc *t* test was used where applicable. Mann-Whitney *U*-test was applied to cumulative clinic scores. Kruskal-Wallis test was applied when multiple groups of clinic curves were compared. Data are shown as means ± SEM. *P* values \<0.05, \<0.01 and \<0.001 were indicated.
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![Oral treatment with *Bacteroides fragilis* PSA protects against murine EAE in a TLR2-dependent manner. Wild-type and TLR2^KO^ mice on C57BL/6 background were prophylactically treated with 100 μg of purified *B. fragilis* PSA or PBS as control by oral gavage every 3 days. Treatment was initiated 6 days before optimal active EAE induction (s.c. injection with MOG~35--55~ peptide plus two doses of i.p. injection with pertussis toxin) and terminated 9 days after disease induction. (**A**) EAE clinic scores were monitored till day 25. Depicted are the combined results of two independent experiments (*n* = 8, per group). Mean ± SEM scores are shown. \*, *P*\< 0.05; \*\*, *P*\< 0.01; \*\*\*, *P*\< 0.001 (Kruskal-Wallis test of all groups). (**B**) Cumulative scores were derived from (**A**) as the sum of clinic scores divided by the number of mice per group. Mean ± SEM scores are shown. *P* value was calculated by Mann-Whitney *U*-test. (**C**) Histological analyses show transversal sections of spinal cords stained with haematoxylin and eosin (H&E) and Luxol fast blue (LFB), and sections of brain stems stained with H&E. H&E stain targeted nucleated cells (red arrows point at the clusters of infiltrating lymphocytes); LFB stain targeted myelin (red arrows point at the demyelination spots). Depicted are representative pictures (magnification 40x) from the indicated EAE-induced groups: PBS-treated WT mice, PSA-treated WT mice, and PSA-treated TLR2^KO^ mice. All samples were collected (*n* = 4 sections per mouse, *n* = 3 mice per group) at the peak of disease. Images in each row are the same treatment group, and in each column are the same staining method. Scale bars:100 μm. (**D**) Brains of PBS or PSA-treated EAE-induced WT mice or PSA-treated EAE-induced TLR2^KO^ mice were harvested at the onset stage of the disease. Relative expression of transcription factors (*Tbx21*, *Stat4*), cytokines (IFNγ, IL-17, IL-6, TNFα, IL-12p40) and chemokines (IP-10, MCP-1, Rantes, MIP-1α, MIP-1β) were measured by qRT-PCR. Mean ± SEM mRNA relative expression from two independent experiments is shown. *P* value was calculated by two-tailed Student's *t* test (*n* = 5--12 for each group).](nihms606319f1){#F1}

![PSA triggers specific signal on CD4 T cells via TLR2 under inflammatory conditions. Wild-type and TLR2^KO^ mice on IL-10 Thy1.1 reporter strain (10BiT) background were orally gavaged with PSA or PBS and induced with optimal active EAE as in [Fig 1A](#F1){ref-type="fig"} setting. At the peak of disease, total leukocytes were isolated from cervical lymph nodes. Flow cytometry analysis was performed to identify the specific CD4 T cell marker(s) triggered by PSA in a TLR2 dependent manner. CD4 T cells were pre-gated and mean fluorescence intensity (MFI) was used to measure the expression level of the indicated markers. Mean ± SEM MFI values were compared between PSA- or PBS-treated WT or TLR2^KO^ mice. Depicted are representative results from two independent experiments (*n* = 4 for each group). *P* value was calculated by one-way ANOVA test.](nihms606319f2){#F2}

![TLR2-dependentPSA expansion of CD39^+^ CD4 T cells is tissue site-specific. Wild-type and TLR2^KO^ mice were treated with the same regimen as described in [Fig 1A](#F1){ref-type="fig"} setting. At the peak of disease, total leukocytes were isolated from cervical lymph nodes (CLNs), mesenteric lymph nodes (MLNs), spleen and whole blood and flow cytometry analysis was performed. Oral PSA administration stimulates CD39 expression on CD4 T cells via TLR2 at both (**A**) CLNs and (**B**) MLNs. CD4 T cells were pre-gated and CD39 expression level was measured in (**A**) and (**B**). Depicted are the typical histograms for each indicated treatment group from two independent experiments (*n* = 3--10, per group). (**C**) TLR2-dependent PSA induction of CD39 signal on CD4 T cells is restricted to CLNs and MLNs. Frequencies of CD39^+^ subsets among CD4 T cells were quantified for the indicated tissue sites. Depicted are combined representative results of two independent experiments (*n* = 6--10, per group). *P* value was calculated by two-tailed Student's *t* test. (**D**) PSA does not influence CD39 signal on CD19 B cells. Frequencies of CD39^+^ subsets among CD19 B cells were quantified for both CLNs and MLNs. Combined representative results of two experiments are shown (*n* = 6--10, per group).](nihms606319f3){#F3}

![Phenotyping cervical lymph node-sourced CD39^+^ versus CD39^−^ CD4 T cells. CLNs were harvested from PSA-gavaged EAE-induced mice (day 18 post EAE induction). Total leukocytes were isolated and analyzed by flow cytometry. (**A**) CD39^+^ CD4 T cells display elevated regulatory signatures as compared to CD39^−^CD4 T cells. CD39^+^ and CD39^−^ CD4 T cell populations were analyzed for the expression of each indicated marker. Depicted are the representative histograms for individual analysis from two independent experiments (*n* = 4--5, per group). **Red line**, CD39^+^CD4 T cells; **blue line**, CD39^−^CD4 T cells; **grey shade**, isotype. (**B**) For each analysis in (**A**), Mean ± SEM MFI values were quantified. **Black**, CD39^+^CD4 T cells; **white**, CD39^−^CD4 T cells; **grey**, corresponding isotype for each indicated marker. *P* value was calculated by two-tailed Student's *t* test (*n* = 4--5 for each group).](nihms606319f4){#F4}

![CD39 signaling is essential for PSA-mediated immuno-regulation during murine EAE. Wild-type and CD39^KO^ C57BL/6 mice were treated with PSA as in [Fig 1A](#F1){ref-type="fig"} and induced sub-optimal active EAE. (**A**) EAE was monitored till day 25. Mean ± SEM scores typical of two independent experiments are shown (*n* = 8, per group). \*, *P*\< 0.05; \*\*, *P*\< 0.01; \*\*\*, *P*\< 0.001. (**B**) Mean ± SEM cumulative scores were calculated from (**A**). (**C**) H&E and LFB staining was performed same as in [Fig 1C](#F1){ref-type="fig"}. Depicted are typical pictures (magnification 40x) from EAE-induced PSA-treated WT or CD39^KO^mice. All samples were collected (*n* = 4 sections per mouse, *n* = 3 mice per group) at the peak of disease. Scale bars: 100 μm. (**D**) Tissues were collected at the onset of EAE and flow cytometric analysis of cells was performed. Mean ± SEM frequencies of activated subsets within total CD4 T cells were compared for the indicated sites (*n* = 4). (**E, F**) Total splenocytes were obtained from wild-type or CD39^KO^ mice treated as in (**A**) on day 14 of EAE induction and cultured *in vitro* with PSA, MOG~35--55~ peptide, or a combination of both at escalating doses (10, 100, or 200 μg/ml of each). Supernatants were collected 48 hr after culture. IL-10 (**E**) and IL-17A (**F**) were measured by ELISA. Mean ± SEM results are combined from two experiments (*n* = 3--4). (**G**) Rag^KO^ recipient mice were reconstituted with splenic CD4 T cells from day 14 EAE-induced wild-type and CD39^KO^ mice treated with PSA as in (**A**) or PBS. Two weeks later, optimal active EAE was introduced into recipients. EAE was monitored till day 21. Mean ± SEM scores representative of two experiments are shown (*n* = 6--8, per group). \*, *P*\< 0.05; \*\*, *P*\< 0.01. (**H**) Mean ± SEM cumulative scores were derived from (**G**). *P* value was calculated by Mann-Whitney *U*-test in (**A**), (**B**) and (**H**), by two-tailed Student's *t* test in (**D**), (**E**) and (**F**) and by Kruskal-Wallis test in (**G**).](nihms606319f5){#F5}
